Dextromethorphan/Quinidine: A Review of Its Use in Adults with Pseudobulbar Affect

An open-label multicenter study to assess the safety of dextromethorphan/quinidine in patients with pseudobulbar affect associated with a range of underlying neurological conditions

(2014) Gary L. Pattee et al.   CURRENT MEDICAL RESEARCH AND OPINION

Neuroanatomy of Pathological Laughing and Crying: A Report of the American Neuropsychiatric Association Committee on Research

(2014) Josef Parvizi et al.   JOURNAL OF NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCES

Involvement of Sigma-1 Receptors in the Antidepressant-like Effects of Dextromethorphan

(2014) Linda Nguyen et al.   PLoS One

Current Concepts in the Pharmacotherapy of Pseudobulbar Affect

(2011) Erik P. Pioro   DRUGS

EFNS guidelines on the Clinical Management of Amyotrophic Lateral Sclerosis (MALS) - revised report of an EFNS task force

(2011) et al.   EUROPEAN JOURNAL OF NEUROLOGY

Pseudobulbar affect: the spectrum of clinical presentations, etiologies and treatments

(2011) Ariel Miller et al.   Expert Review of Neurotherapeutics

Dextromethorphan Plus Ultra Low-Dose Quinidine Reduces Pseudobulbar Affect

(2010) Erik P. Pioro et al.   ANNALS OF NEUROLOGY

Effect of metabolic blockade on the psychoactive effects of dextromethorphan

(2009) Laurie A. Zawertailo et al.   HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL

Effects of Dextromethorphan/Quinidine on Auditory Event-Related Potentials in Multiple Sclerosis Patients With Pseudobulbar Affect

(2009) Guy Haiman et al.   JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY

Practice Parameter update: The care of the patient with amyotrophic lateral sclerosis: Multidisciplinary care, symptom management, and cognitive/behavioral impairment (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology

(2009) R. G. Miller et al.   NEUROLOGY